TY - JOUR
T1 - Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia
T2 - Report from the Israeli Study Group of Childhood Leukemia
AU - Elitzur, Sarah
AU - Arad-Cohen, Nira
AU - Barzilai-Birenboim, Shlomit
AU - Ben-Harush, Miriam
AU - Bielorai, Bella
AU - Elhasid, Ronit
AU - Feuerstein, Tamar
AU - Gilad, Gil
AU - Gural, Alexander
AU - Kharit, Mira
AU - Litichever, Naomi
AU - Nirel, Ronit
AU - Weinreb, Sigal
AU - Wolach, Ofir
AU - Toren, Amos
AU - Izraeli, Shai
AU - Jacoby, Elad
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2019
Y1 - 2019
N2 - Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.
AB - Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.
KW - blinatumomab
KW - childhood acute lymphoblastic leukemia
KW - immunotherapy
KW - treatment-related toxicity
UR - http://www.scopus.com/inward/record.url?scp=85068523452&partnerID=8YFLogxK
U2 - 10.1002/pbc.27898
DO - 10.1002/pbc.27898
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31264788
AN - SCOPUS:85068523452
SN - 1545-5009
VL - 66
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 10
M1 - e27898
ER -
